Literature DB >> 15289794

Time response of cytochrome P450 1A2 activity on cessation of heavy smoking.

Mirko S Faber1, Uwe Fuhr.   

Abstract

BACKGROUND AND
OBJECTIVE: Cytochrome P450 (CYP) 1A2 activity is induced by cigarette smoking. Thus smoking cessation in patients while they are undergoing therapy with a CYP1A2 substrate such as theophylline or clozapine increases its concentrations and may cause adverse effects. Our objective was to determine the time course of CYP1A2 activity changes after smoking cessation in heavy smokers as the basis for dosing adaptation schemes.
METHODS: The study was conducted in 8 men and 4 women (all white) who smoked 20 cigarettes or more per day. Sudden smoking cessation was carried out after a 14-day run-in period. Subjects were phenotyped for CYP1A2 activity at 6, 4, and 1 day before smoking cessation and at 0, 1, 2, 3, 6, 8, 10, and 13 days thereafter by use of the paraxanthine-to-caffeine ratio in plasma 6 hours after a 148-mg caffeine test dose. A monoexponential decay of CYP1A2 activity to a residual value was fitted to the data by nonlinear regression analysis.
RESULTS: On cessation of smoking, initial caffeine clearance (estimated geometric means and 95% confidence intervals) decreased significantly (P <.01), by 36.1% (30.9%-42.2%), from 2.47 mL. min(-1). kg(-1) body weight (2.03-3.00 mL. min(-1). kg(-1) body weight) to a new steady state of 1.53 mL. min(-1). kg(-1) body weight (1.24-1.89 mL. min(-1). kg(-1) body weight). The apparent half-life of CYP1A2 activity decrease was 38.6 hours (27.4-54.4 hours).
CONCLUSION: Doses of CYP1A2 substrates with a narrow therapeutic range should be decreased immediately on cessation of heavy smoking. As a rule of thumb, a stepwise daily dose reduction of approximately 10% until the fourth day after smoking cessation is proposed, which should be accompanied by therapeutic drug monitoring.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15289794     DOI: 10.1016/j.clpt.2004.04.003

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  33 in total

1.  PharmGKB summary: caffeine pathway.

Authors:  Caroline F Thorn; Eleni Aklillu; Ellen M McDonagh; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2012-05       Impact factor: 2.089

Review 2.  Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Authors:  Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

3.  Smoking cessation and neuropsychiatric adverse events: are family physicians caught between a rock and a hard place?

Authors:  Charl Els; Diane Kunyk; Harkirat Sidhu
Journal:  Can Fam Physician       Date:  2011-06       Impact factor: 3.275

Review 4.  Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products.

Authors:  Gail D Anderson; Lingtak-Neander Chan
Journal:  Clin Pharmacokinet       Date:  2016-11       Impact factor: 6.447

Review 5.  Cigarette smoking and clopidogrel interaction.

Authors:  Kristopher J Swiger; Omair Yousuf; Kevin P Bliden; Udaya S Tantry; Paul A Gurbel
Journal:  Curr Cardiol Rep       Date:  2013-05       Impact factor: 2.931

6.  Smoking and opioid detoxification: behavioral changes and response to treatment.

Authors:  Paolo Mannelli; Li-Tzy Wu; Kathleen S Peindl; David A Gorelick
Journal:  Nicotine Tob Res       Date:  2013-04-09       Impact factor: 4.244

7.  Impact of cigarette smoking on P2Y12 receptor binding activity before and after clopidogrel therapy in patients with coronary artery disease.

Authors:  Jung Rae Cho; Bhaloo Desai; Michael J Haas; Fabiana Rollini; Francesco Franchi; Ana Muñiz-Lozano; Antonio Tello-Montoliu; Elisabetta Ferrante; Luis A Guzman; Theodore A Bass; Dominick J Angiolillo
Journal:  J Cardiovasc Transl Res       Date:  2013-12-20       Impact factor: 4.132

Review 8.  Effects of tobacco smoking and nicotine on cancer treatment.

Authors:  William P Petros; Islam R Younis; James N Ford; Scott A Weed
Journal:  Pharmacotherapy       Date:  2012-10       Impact factor: 4.705

9.  Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine.

Authors:  Janne T Backman; Marika T Schröder; Pertti J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  2007-10-23       Impact factor: 2.953

10.  Interaction between cigarette smoking and clinical benefit of clopidogrel.

Authors:  Nihar R Desai; Jessica L Mega; Songtao Jiang; Christopher P Cannon; Marc S Sabatine
Journal:  J Am Coll Cardiol       Date:  2009-04-14       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.